Nabriva Therapeutics plc, a clinical stage biopharmaceutical company, engages in the research and development of anti-infective agents to treat infections in humans. The company focuses on the pleuromutilin class of antibiotics. Its lead product candidate is lefamulin, which is in Phase III clinical trials in intravenous and oral formulations for the treatment of community-acquired bacterial pneumonia; and has completed Phase II clinical trials for the treatment of acute bacterial skin and skin structure infection. The company is also developing BC-7013, a semi-synthetic compound derived from pleuromutilin, which has completed a Phase 1 clinical trial for the treatment of Gram-positive infections, including uncomplicated skin and skin structure infections. In addition, it is developing lefamulin for use in the treatment of ventilator-associated bacterial pneumonia or hospital-acquired bacterial pneumonia and sexually transmitted infections. The company was formerly known as Nabriva Therapeutics Forschungs GmbH and changed its name to Nabriva Therapeutics plc in 2007. Nabriva Therapeutics plc was incorporated in 2005 and is headquartered in Dublin, Ireland.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryN/A
SectorMedical
SymbolNASDAQ:NBRV
CUSIPN/A
Phone610-816-6640
Debt
Debt-to-Equity RatioN/A
Current Ratio8.66
Quick Ratio8.66
Price-To-Earnings
Trailing P/E Ratio-1.37
Forward P/E Ratio-1.88
P/E GrowthN/A
Sales & Book Value
Annual Sales$5.32 million
Price / Sales26.16
Cash FlowN/A
Price / CashN/A
Book Value$2.24 per share
Price / Book1.53
Profitability
EPS (Most Recent Fiscal Year)($2.49)
Net Income$-74,350,000.00
Net Margins-600.34%
Return on Equity-79.30%
Return on Assets-66.97%
Miscellaneous
Employees88
Outstanding Shares40,690,000
Market Cap$137.93
Nabriva Therapeutics (NASDAQ:NBRV) Frequently Asked Questions
What is Nabriva Therapeutics' stock symbol?
Nabriva Therapeutics trades on the NASDAQ under the ticker symbol "NBRV."
How were Nabriva Therapeutics' earnings last quarter?
Nabriva Therapeutics PLC - (NASDAQ:NBRV) released its earnings results on Tuesday, May, 8th. The biotechnology company reported ($0.36) earnings per share (EPS) for the quarter, beating the Zacks' consensus estimate of ($0.59) by $0.23. The biotechnology company earned $7.55 million during the quarter, compared to analyst estimates of $1.27 million. Nabriva Therapeutics had a negative return on equity of 79.30% and a negative net margin of 600.34%. View Nabriva Therapeutics' Earnings History.
When is Nabriva Therapeutics' next earnings date?
What price target have analysts set for NBRV?
9 brokerages have issued 1 year price targets for Nabriva Therapeutics' shares. Their forecasts range from $10.00 to $24.00. On average, they expect Nabriva Therapeutics' stock price to reach $17.75 in the next twelve months. This suggests a possible upside of 419.0% from the stock's current price. View Analyst Ratings for Nabriva Therapeutics.
What is the consensus analysts' recommendation for Nabriva Therapeutics?
9 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Nabriva Therapeutics in the last year. There are currently 9 buy ratings for the stock, resulting in a consensus recommendation of "Buy."
What are Wall Street analysts saying about Nabriva Therapeutics stock?
Here are some recent quotes from research analysts about Nabriva Therapeutics stock:
- 1. According to Zacks Investment Research, "Nabriva Therapeutics is a biopharmaceutical company engaged in the research and development of new medicines to treat serious bacterial infections, with a focus on the pleuromutilin class of antibiotics. Nabriva Therapeutics' medicinal chemistry expertise has enabled targeted discovery of novel pleuromutilins, including both intravenous and oral formulations. Nabriva Therapeutics' lead product candidate, lefamulin, is a novel semi-synthetic pleuromutilin antibiotic with the potential to be the first-in-class available for systemic administration in humans. The company believes that lefamulin is the first antibiotic with a novel mechanism of action to have reached late-stage clinical development in more than a decade. Nabriva has announced positive topline data for lefamulin from the first of its two global, registrational Phase 3 clinical trials evaluating lefamulin in patients with moderate to severe community-acquired bacterial pneumonia (CABP). " (7/19/2018)
- 2. Needham & Company LLC analysts commented, "Nabriva reported 1Q18 financial results today and we spoke w/ mgmt for an update. Mgmt reiterated guidance for top-line results from the second of two Phase 3 trials of lead antibiotic lefamulin in Community Pneumonia (CABP) in 2Q18. We continue to expect a positive outcome and reiterate BUY rating. We believe the opportunity for lefamulin in Community Pneumonia is misunderstood and underappreciated by investors. We acknowledge challenges for antibiotics within the hospital, but believe oral lefamulin can be relevant in the large outpatient community setting." (5/8/2018)
- 3. HC Wainwright analysts commented, "Updated Results from SITC Confirm IMO-2125 Clinical Benefit; Reiterate Buy IMO-2125 activates innate immune response against tumor. Last week we attended the annual meeting for Society for Immunotherapy of Cancer (SITC) held in National Harbor, Maryland. At the conference, Dr. Haymaker from MD Anderson Cancer Center presented additional results from the ongoing Phase 1/2 clinical study of IMO-2125, a TLR9 agonist from Idera. Recall, IMO-2125 is being investigated as a combinational therapy together with Bristol-Myers Squibb’s (BMY; not rated) Yervoy (ipilimumab) for the treatment of PD-1 refractory melanoma. Previously, it was reported that the combination of IMO-2125 and ipilimumab achieved an overall response rate (ORR) of 44%. The updated results presented at the SITC conference included an additional patient with confirmed response, which improved the ORR from the study to 50% (5 out of 10 patients). Importantly, gene expression analysis in patients’ tumor biopsies, taken 24 hours after IMO-2125 injections, suggests that IMO-2125 upregulates interferon-alpha production, promotes dendritic cells maturation and the inflow of macrophages at the tumor site. Moreover, considering that ipilimumab has not yet been administered at the time of the biopsy, the observed activation of immune system can be fully attributed to IMO-2125, rather than the drug combination. In our view, these results provide additional confidence in the clinical activity of IMO-2125 and potential success of the planned Phase 3 study, which is expected to start in 1Q18." (11/16/2017)
- 4. Cantor Fitzgerald analysts commented, "Yesterday, after market close, Nabriva announced that Elyse Seltzer, M.D., is resigning as CMO effective 9/30/2017." (9/1/2017)
Are investors shorting Nabriva Therapeutics?
Nabriva Therapeutics saw a decrease in short interest during the month of June. As of June 15th, there was short interest totalling 987,003 shares, a decrease of 23.9% from the May 31st total of 1,296,317 shares. Based on an average daily volume of 347,534 shares, the short-interest ratio is currently 2.8 days. Approximately 3.2% of the company's shares are short sold. View Nabriva Therapeutics' Current Options Chain.
Who are some of Nabriva Therapeutics' key competitors?
Some companies that are related to Nabriva Therapeutics include CannTrust (CNTTF), Keryx Biopharmaceuticals (KERX), Aduro BioTech (ADRO), Evolus (EOLS), Depomed (DEPO), Lannett (LCI), ArQule (ARQL), Arcus Biosciences (RCUS), Stemline Therapeutics (STML), Aurinia Pharmaceuticals (AUPH), Cytokinetics (CYTK), ZEALAND PHARMA/S (ZEAL), Magenta Therapeutics (MGTA), Synergy Pharmaceuticals (SGYP) and Zymeworks (ZYME).
Who are Nabriva Therapeutics' key executives?
Nabriva Therapeutics' management team includes the folowing people:
- Dr. Colin Broom, CEO & Director (Age 62)
- Mr. Gary L. Sender, Chief Financial Officer (Age 56)
- Mr. Steven P. Gelone Pharm. D, Chief Scientific Officer (Age 50)
- Mr. Thomas Lembck, Chief Information Officer
- Mr. David Garrett, Head of Investor Relations, VP & Corp. Controller
Has Nabriva Therapeutics been receiving favorable news coverage?
Headlines about NBRV stock have been trending somewhat positive on Friday, according to Accern Sentiment Analysis. Accern identifies positive and negative press coverage by reviewing more than 20 million news and blog sources in real time. Accern ranks coverage of publicly-traded companies on a scale of negative one to positive one, with scores closest to one being the most favorable. Nabriva Therapeutics earned a news impact score of 0.12 on Accern's scale. They also assigned media headlines about the biotechnology company an impact score of 47.60 out of 100, indicating that recent press coverage is somewhat unlikely to have an impact on the stock's share price in the next few days.
How do I buy shares of Nabriva Therapeutics?
Shares of NBRV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Nabriva Therapeutics' stock price today?
One share of NBRV stock can currently be purchased for approximately $3.42.
How big of a company is Nabriva Therapeutics?
Nabriva Therapeutics has a market capitalization of $137.93 million and generates $5.32 million in revenue each year. The biotechnology company earns $-74,350,000.00 in net income (profit) each year or ($2.49) on an earnings per share basis. Nabriva Therapeutics employs 88 workers across the globe.
How can I contact Nabriva Therapeutics?
Nabriva Therapeutics' mailing address is 56 FITZWILLIAM SQUARE, DUBLIN L2, 19406. The biotechnology company can be reached via phone at 610-816-6640 or via email at [email protected]
MarketBeat Community Rating for Nabriva Therapeutics (NASDAQ NBRV)
MarketBeat's community ratings are surveys of what our community members think about Nabriva Therapeutics and other stocks. Vote "Outperform" if you believe NBRV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe NBRV will underperform the S&P 500 over the long term. You may vote once every thirty days.
